Analyzing Organigram Global (OGI) and Its Competitors

Organigram Global (NASDAQ:OGI) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its rivals? We will compare Organigram Global to similar businesses based on the strength of its dividends, institutional ownership, analyst recommendations, risk, profitability, earnings and valuation.

Risk & Volatility

Organigram Global has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Organigram Global’s rivals have a beta of 2.57, suggesting that their average stock price is 157% more volatile than the S&P 500.

Institutional & Insider Ownership

34.6% of Organigram Global shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 0.1% of Organigram Global shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Organigram Global and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	0	1	2	0	2.67
Organigram Global Competitors	4281	10557	18338	829	2.46

As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 19.75%. Given Organigram Global’s rivals higher probable upside, analysts plainly believe Organigram Global has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Organigram Global and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Organigram Global	$185.07 million	-$17.70 million	1.92
Organigram Global Competitors	$1.89 billion	$135.83 million	12.23

Organigram Global’s rivals have higher revenue and earnings than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Organigram Global and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organigram Global	28.14%	-13.39%	-8.67%
Organigram Global Competitors	-304.51%	-178.77%	-22.17%

Summary

Organigram Global rivals beat Organigram Global on 8 of the 13 factors compared.

Organigram Global Company Profile

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.